Difficulty: Medium
Average Score: 94%
Practice
Aspirin prolongs bleeding time by inhibiting the synthesis of
Correct answer
D
Rationale
The correct answer is D) Thromboxane A2 in platelets.
Rationale:
Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits the enzyme cyclooxygenase (COX). Thromboxane A2 is a product of the COX pathway and is essential for platelet aggregation and vasoconstriction. By inhibiting thromboxane A2 synthesis in platelets, aspirin causes a decrease in platelet aggregation and prolongs bleeding time.
Why other options are wrong:
A) Clotting factors in liver: Aspirin does not directly affect the synthesis of clotting factors in the liver.
B) Prostacyclin in vascular endothelium: Aspirin actually promotes the synthesis of prostacyclin, which has anti-thrombotic effects.
C) Cyclic AMP in platelets: Aspirin's mechanism of action is not related to cyclic AMP inhibition in platelets.
Educational context:
Understanding how aspirin affects hemostasis through its inhibition of thromboxane A2 is crucial for healthcare professionals managing patients on antiplatelet therapy. This knowledge is essential in the context of preventing and managing cardiovascular diseases, as well as understanding the potential side effects and interactions of hematological drugs. By grasping the pharmacological actions of aspirin, healthcare providers can make informed decisions regarding patient care and treatment strategies.
Rationale:
Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits the enzyme cyclooxygenase (COX). Thromboxane A2 is a product of the COX pathway and is essential for platelet aggregation and vasoconstriction. By inhibiting thromboxane A2 synthesis in platelets, aspirin causes a decrease in platelet aggregation and prolongs bleeding time.
Why other options are wrong:
A) Clotting factors in liver: Aspirin does not directly affect the synthesis of clotting factors in the liver.
B) Prostacyclin in vascular endothelium: Aspirin actually promotes the synthesis of prostacyclin, which has anti-thrombotic effects.
C) Cyclic AMP in platelets: Aspirin's mechanism of action is not related to cyclic AMP inhibition in platelets.
Educational context:
Understanding how aspirin affects hemostasis through its inhibition of thromboxane A2 is crucial for healthcare professionals managing patients on antiplatelet therapy. This knowledge is essential in the context of preventing and managing cardiovascular diseases, as well as understanding the potential side effects and interactions of hematological drugs. By grasping the pharmacological actions of aspirin, healthcare providers can make informed decisions regarding patient care and treatment strategies.